Nektar Therapeutics (NKTR)
68.78
-0.20
(-0.29%)
USD |
NASDAQ |
Mar 02, 11:19
Nektar Therapeutics Research and Development Expense (Annual) : 119.64M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Rigel Pharmaceuticals, Inc. | 23.38M |
| Insmed, Inc. | 771.09M |
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| Ironwood Pharmaceuticals, Inc. | 93.26M |
| Lyell Immunopharma, Inc. | 152.28M |